Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective.

Cellular & molecular biology letters·2026

Same author

Correlations between inflammatory biomarkers and clinicopathological features in surgically resected thymic epithelial tumors: implications for preoperative diagnosis.

PeerJ·2026

Same author

Anti-SARS-CoV-2 response in alveolar blood sample and bronchoalveolar lavage fluid of individuals vaccinated with inactivated COVID-19 vaccines.

Human vaccines & immunotherapeutics·2026

Same author

GhTUA2 promote roots elongation through regulating cell wall synthesis in cotton.

Plant science : an international journal of experimental plant biology·2026

Same author

A novel wearable interface based on IMUs for robotic endoscopy.

International journal of computer assisted radiology and surgery·2026

Same author

Effect of ethanol vapor on anti-browning and antioxidant properties of fresh-cut stem lettuce via regulation of reactive oxygen species metabolism.

Scientific reports·2026

Same journal

CitM mediates hydroxycitrate (HCA) uptake: insights from heterologous expression in Escherichia coli, Bacillus subtilis mutant analysis and membrane topology prediction.

Biotechnology letters·2026

Same journal

Foliar and root absorption of LDH nanosheets loaded with dsRNAs efficiently silenced the expression of whitefly Bemisia tabaci Laccase 1 and Vitellogenin Receptor genes for their effective control.

Biotechnology letters·2026

Same journal

Morfo-anatomical insights into the germination and protocorm growth of the endangered Vanilla lindmaniana (Orchidaceae).

Biotechnology letters·2026

Same journal

Biosynthetic glycosylation as a critical structural determinant of antifungal activity in venturicidin A.

Biotechnology letters·2026

Same journal

Scaling up biomass production of Vishniacozyma victoriae and semi-commercial testing for post-harvest control of pome fruit disease.

Biotechnology letters·2026

Same journal

Efficient production of L-asparaginase using recombinant Pichia pastoris and strategy to eliminate glutaminase activity.

Biotechnology letters·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Dec 29, 2025

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Nanobody against PDL1.

Shufeng Li¹, Kunpeng Jiang², Ting Wang²

¹Key Laboratory of Developmental Genes and Human Disease in Ministry of Education, Department of Biochemistry and Molecular Biology, Medical School of Southeast University, Nanjing, 210009, China. shufengli@seu.edu.cn.

Biotechnology Letters

|February 2, 2020

Summary

This summary is machine-generated.

Researchers developed novel anti-PDL1 nanobodies from a camel library. These nanobodies target programmed death ligand 1 (PDL1), a protein crucial for cancer immune evasion, offering potential new cancer therapies.

Keywords:

Nanobody Programmed death 1 Programmed death ligand 1 Tumor

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Dec 29, 2025

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Programmed death ligand 1 (PDL1) is a key immune checkpoint protein that inhibits T cell responses.
PDL1 facilitates cancer immune evasion and tumor growth, making it a significant therapeutic target.
The B7 family includes PDL1 and PDL2, which bind to the programmed death 1 (PD1) receptor on T cells.

Purpose of the Study:

To develop novel therapeutic agents targeting PDL1.
To select specific nanobodies against PDL1 using advanced biotechnology.
To explore new strategies for overcoming cancer immune evasion.

Main Methods:

Utilized phage display technology for selection.
Employed a high-quality dromedary camel immune library.
Screened for nanobodies with high specificity for PDL1.

Main Results:

Successfully selected three nanobodies specific to PDL1 (anti-PDL1-VHHs).
Demonstrated the potential of nanobodies as targeted inhibitors of PDL1.
Established a method for generating potent anti-PDL1 VHHs.

Conclusions:

The developed anti-PDL1 nanobodies represent promising candidates for cancer immunotherapy.
Nanobody technology offers a viable approach for developing targeted cancer therapies.
Targeting PDL1 remains a critical strategy in overcoming tumor-induced immunosuppression.